QuidelOrtho Corp (QDEL) bonds
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)
Close on Nov 18, 2026Market cap $656.27MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 27, 2026
Total debt
$2.94B
$424.40M due within a year
Net debt
$2.77B
After $166.40M of cash
Implied interest rate
6.92%
FY2025 interest ÷ average debt
Interest coverage
-5.2×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 28, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in QuidelOrtho's 10-Q for the period ended Jun 28, 2026
QuidelOrtho's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn |
|---|---|---|---|
| Credit Agreement | $700.00M | $426.50M | $250.00M |
| Delayed Draw Term Loan A | $100.00M | – | $100.00M |
| Term Loan A | $1.15B | – | $1.14B |
| Term Loan A Facilities | – | – | $1.22B |
| Term Loan B | $1.45B | – | $1.44B |
See a number that looks wrong?